Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Science ShareTwitterFacebookXingLinkedin You May Also Like Science 25. Mai 2023 CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes Science 25. Mai 2023 Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. Science 25. Mai 2023 (Bersacapavir) In Participants With Moderate Hepatic Impairment.